May 13 |
Boundless Bio GAAP EPS of -$12.27 misses by $11.54
|
May 13 |
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
|
May 6 |
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
|
Apr 11 |
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
|
Apr 8 |
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
|
Mar 28 |
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
|
Mar 28 |
Boundless Bio prices $100M IPO at $16 per share
|
Mar 27 |
Boundless Bio Announces Pricing of Initial Public Offering
|